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A
 
BSTRACT
 
Background
 
Short-term preoperative radiotherapy
and total mesorectal excision have each been shown
to improve local control of disease in patients with
resectable rectal cancer. We conducted a multicenter,
randomized trial to determine whether the addition
of preoperative radiotherapy increases the benefit of
total mesorectal excision.
 
Methods
 
We randomly assigned 1861 patients with
resectable rectal cancer either to preoperative radio-
therapy (5 Gy on each of five days) followed by total
mesorectal excision (924 patients) or to total meso-
rectal excision alone (937 patients). The trial was con-
ducted with the use of standardization and quality-
control measures to ensure the consistency of the
radiotherapy, surgery, and pathological techniques.
 
Results
 
Of the 1861 patients randomly assigned
to one of the two treatment groups, 1805 were eligi-
ble to participate. The overall rate of survival at two
years among the eligible patients was 82.0 percent
in the group assigned to both radiotherapy and sur-
gery and 81.8 percent in the group assigned to sur-
gery alone (P=0.84). Among the 1748 patients who un-
derwent a macroscopically complete local resection,
the rate of local recurrence at two years was 5.3 per-
cent. The rate of local recurrence at two years was
2.4 percent in the radiotherapy-plus-surgery group
and 8.2 percent in the surgery-only group (P<0.001).
 
Conclusions
 
Short-term preoperative radiotherapy
reduces the risk of local recurrence in patients with
rectal cancer who undergo a standardized total mes-
orectal excision. (N Engl J Med 2001;345:638-46.)
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OCAL recurrence is a serious problem in
the treatment of rectal cancer, since it causes
disabling symptoms and is difficult to treat.
 
1,2
 
There is a high incidence of local recur-
rence (15 to 45 percent) after conventional surgery,
in which blunt dissection of the rectal fascia often
fails to remove all the tissue that may bear tumor.
 
3-5
 
In an attempt to improve local control and sur-
vival after conventional surgery, radiotherapy has been
given. The only randomized trial that compared pre-
operative and postoperative radiotherapy showed the
superiority of preoperative radiotherapy for local con-
trol.
 
6
 
 The Swedish Rectal Cancer Trial found that
L
 
preoperative radiotherapy also improved the rate of
survival at five years.
 
7
 
 A recent meta-analysis
 
8
 
 conclud-
ed that the combination of preoperative radiotherapy
and surgery, as compared with surgery alone, signif-
icantly improved overall survival and cancer-specific
survival.
The recognition that involvement of the circum-
ferential margin by tumor cells is important in local
recurrences has led to the general use of total mes-
orectal excision,
 
9-13
 
 in which the entire mesorectum is
enveloped and resected by precise, sharp dissection.
Improvements in local control with this technique
have been shown, mainly in retrospective series.
 
9-12,14
 
In previous studies of radiotherapy for rectal cancer,
surgery was not standardized. Since surgical technique
is a key factor in the success of tumor control,
 
15-17
 
standardization and quality control with respect to
surgery are indispensable for evaluating the effects of
adjuvant therapy. Optimal quality must also include
the use of standardized methods of pathological ex-
amination.
 
18
 
 A prospective, randomized trial was or-
ganized by the Dutch Colorectal Cancer Group to
investigate the efficacy of preoperative radiotherapy
in combination with standardized total mesorectal
excision in patients with rectal cancer.
 
19
 
 In this arti-
cle, we present the results of the trial after a median
follow-up of two years.
 
METHODS
 
Eligibility, Randomization, and Sample Size
 
Patients were enrolled between January 1996 and December
1999. To be eligible, patients had to have histologically confirmed
adenocarcinoma of the rectum, without evidence of distant me-
tastases, and the inferior margin of the tumor had to be located
not farther than 15 cm from the anal verge and below the level
of S1–2. Patients with fixed tumors or tumors that were treated
The New England Journal of Medicine 
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by local (transanal) resection were excluded. Patients with previous
or coexisting cancer and those who had previously undergone large-
bowel surgery, chemotherapy, or radiotherapy of the pelvis were
also excluded.
After informed consent had been obtained, we randomly as-
signed the patients to treatment with preoperative radiation (5 Gy
on each of five days) followed by total mesorectal excision or to
total mesorectal excision alone. Randomization was performed at
the central trial office and was based on permuted blocks of six,
with stratification according to center and the expected type of
operation (low anterior resection or abdominoperineal resection).
The trial was approved by the medical ethics committees of all the
participating hospitals. The trial design and the calculation of the
sample size have been described in detail elsewhere.
 
19
 
Follow-up
 
Clinical evaluation every three months during the first year af-
ter surgery and yearly thereafter for at least two more years was
mandatory and included yearly liver imaging and endoscopy. Local
recurrence was defined as evidence of a tumor within the lesser pel-
vis or the perineal wound. Distant recurrence was defined as evi-
dence of a tumor in any other area. Recurrence at the colostomy
site or in the inguinal region was also classified as distant recurrence.
 
Quality Control
 
In the Netherlands, participating surgeons attended workshops
and symposiums, saw instructional videotapes, and were monitored
by specially trained instructor surgeons. At each hospital, the first
five total mesorectal excisions were supervised by an instructor
surgeon.
 
19
 
 Pathologists were trained to identify lateral spread of
tumor according to the protocol of Quirke et al.
 
18
 
 The results of
histopathological examination of the specimens were reviewed by
a panel of supervising pathologists and a quality manager.
 
20
 
 Pa-
tients’ eligibility and treatment and the details of follow-up were
checked by study coordinators. Local and distant recurrences were
confirmed radiologically or histologically and checked by a radi-
ation oncologist.
In Sweden, the technique of total mesorectal excision was in-
troduced on a national basis several years ago,
 
12,13
 
 as was the pro-
tocol of Quirke et al.
 
18
 
 The European Organization for Research
and Treatment of Cancer participated in this trial under protocol
40971. Visits to other participating hospitals and specialists were
made before the start of the trial to ensure the quality of treatment
at those sites. For logistic reasons, no quality control with respect
to radiotherapy, surgery, or pathological examination was performed
outside the Netherlands during the trial.
 
Statistical Analysis
 
Case-report forms were sent to the central trial office, where in-
formation on the forms was entered into a data base and analyzed
with SPSS statistical software (version 9.0 for Windows, SPSS,
Chicago). Chi-square tests were used to compare proportions.
Mann–Whitney tests were used to compare quantitative and or-
dinal variables. Univariate analyses of survival were carried out by
the Kaplan–Meier method, and the evaluation of differences be-
tween the two groups was performed with the log-rank test. The
Cox proportional-hazards model was used to calculate hazard ra-
tios and 95 percent confidence intervals in the univariate and mul-
tivariate analyses. A two-sided P value of 0.05 or less was considered
to indicate statistical significance.
The starting point for the analyses of survival and recurrence
was the day of surgery. Data on patients who were alive or free of
recurrence were censored at the time of the last follow-up. The
analysis of overall survival was performed on an intention-to-treat
basis and thus included all the eligible patients. The rate of local re-
currence was calculated on the basis of the number of eligible pa-
tients who underwent a macroscopically complete local resection.
The rate of distant recurrence was calculated on the basis of the
number of eligible patients who did not have distant metastasis at
the time of surgery. The overall rate of recurrence was calculated
on the basis of the number of eligible patients who had macroscop-
ically complete local resection without distant metastasis. Analyses
of postoperative morbidity and mortality were based on the total
number of eligible patients who underwent resection.
 
RESULTS
 
Patients
 
A total of 1861 patients were randomly assigned to
one of the two treatment groups. There were 1530
patients from 84 Dutch hospitals, 228 from 13 Swed-
ish hospitals, and 103 from 11 other European and
Canadian centers. Of these 1861 patients, a total of
56 were found to be ineligible before randomization,
including 4 patients for whom there was no infor-
mation on eligibility. Our analysis therefore included
1805 eligible patients. Of these, 1653 patients had a
curative resection. Of the remaining 152 patients, 57
did not undergo a macroscopically complete local re-
section, and 95 were found to have distant metastasis
at surgery (Table 1). The characteristics of the 1805
patients who were eligible for the study and the fea-
tures of their tumors were similar in the two treat-
ment groups (Table 2). In 28 patients (2 percent), no
tumor was found in the resected specimen, despite a
preoperative biopsy that showed an adenocarcinoma.
 
Protocol Violations
 
Patients with major or minor protocol violations,
or both, were included in all the analyses.
 
Major Violations
 
Of the 897 eligible patients assigned to undergo
radiotherapy before total mesorectal excision, 29 did
not receive preoperative radiotherapy for the follow-
ing reasons: known metastases (8 patients), carcinoma
in situ (1), sigmoid carcinoma (3), a second cancer
(1), withdrawal of informed consent (11), and phys-
ical limitations that made radiotherapy impossible (5).
Long-term preoperative radiotherapy was given to sev-
en patients for locally advanced tumors. One patient
was unable to tolerate surgery and was treated with
long-term radiotherapy alone. Preoperative radiother-
apy was discontinued in 14 patients, mainly because
of neurotoxicity.
Of the 908 eligible patients assigned to total mes-
orectal excision alone, 3 patients withdrew their in-
formed consent and requested radiotherapy (5 Gy on
each of five days), and 8 patients had advanced local
tumors for which long-term preoperative radiother-
apy was given.
Postoperative adjuvant therapy was not allowed in
patients who had microscopically tumor-free margins
without spillage of tumor cells during the operation.
Of 1759 eligible patients with available information
on margins and tumor spillage, 1351 (77 percent) had
tumor-free margins without tumor spillage. Eighty-
five of these patients (38 in the group assigned to ra-
diotherapy and surgery and 47 in the group assigned
to surgery alone) received adjuvant therapy (chemo-
The New England Journal of Medicine 
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therapy, radiotherapy, or chemoradiotherapy), which
was a major protocol violation.
 
Minor Violations
 
Of the 846 eligible patients randomly assigned to
preoperative radiotherapy who received the total dose
of 25 Gy, the interval between the first day of radio-
therapy and the day of surgery exceeded 10 days in
110 patients (13 percent). In 127 of the patients (15
percent), the upper border of the treatment field was
at the level of S1–2 instead of at the promontory,
and in 161 of the patients undergoing an abdomino-
perineal resection (19 percent), the perineum was
not included in the treated volume.
 
Postoperative Morbidity and Mortality
 
The median interval between randomization and
surgery was 21 days in the group assigned to radio-
therapy and surgery and 14 days in the group assigned
to surgery alone. The patients assigned to radiothera-
py and surgery lost slightly more blood during the op-
eration than those assigned to surgery alone (median
loss, 1000 vs. 900 ml; P<0.001), and of the patients
who had an abdominoperineal resection, those as-
signed to radiotherapy had more perineal complica-
tions than those assigned to surgery alone (26 per-
cent vs. 18 percent, P=0.05). No other significant
differences with respect to postoperative morbidity
and mortality were found between the two groups.
 
*Percentages are based on the total numbers of patients randomly assigned to one of the two treat-
ment groups.
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RADIOTHERAPY
PLUS
 
 
 
SURGERY
SURGERY
ALONE
 
no. (%)
 
Randomly assigned to treatment 1861 924 937
Ineligible for participation
No adenocarcinoma
Fixed tumor
Tumor treated by transanal resection
Tumor >15 cm from anal verge
Previous cancer
Coexisting cancer
Previous large-bowel surgery, pelvic radiotherapy,
or chemotherapy
No information on eligibility
56
8
2
2
5
21
11
3
4
27
5
0
2
4
8
4
2
2
29
3
2
0
1
13
7
1
2
Eligible for participation
Incomplete local resection
Without distant metastases
With distant metastases
Complete local resection
With distant metastases
Without distant metastases (curative)
1805 (97)
31
26
1748 (94)
95
1653 (89)
897 (97)
10
14
873 (94)
47
826 (89)
908 (97)
21
12
875 (93)
48
827 (88)
*Characteristics were unknown in some cases because not all case-report
forms were received. Because of rounding, not all percentages total 100.
TNM denotes tumor–node–metastasis.
†A Hartmann resection is a low anterior resection without the construc-
tion of an anastomosis.
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Age — yr
Median
Range
65
26–88
66
23–92
0.79
Sex — no. (%)
Male
Female
573 (64)
324 (36)
578 (64)
330 (36)
0.92
Distance of tumor from 
anal verge — no. (%)
10.1–15 cm
5.1–10 cm
«5 cm
Unknown
267 (30)
384 (43)
244 (27)
2 (<1)
280 (31)
364 (40)
263 (29)
1 (<1)
0.48
Type of resection — no. (%)
None
Low anterior
Abdominoperineal
Hartmann†
Unknown
16 (2)
579 (65)
251 (28)
50 (6)
1 (<1)
29 (3)
604 (67)
234 (26)
40 (4)
1 (<1)
0.12
TNM stage — no. (%)
0
I
II
III
IV
Unknown or no resection
11 (1)
265 (30)
252 (28)
300 (33)
61 (7)
8 (<1)
17 (2)
244 (27)
245 (27)
324 (36)
61 (7)
17 (2)
0.53
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Follow-up
 
As of February 2001, surviving eligible patients
without local recurrence had been followed for a me-
dian of 24.9 months (range, 1.1 to 56.0). Of these pa-
tients, 87 percent were followed for at least one year,
54 percent for at least two years, 24 percent for at
least three years, and 5 percent for at least four years.
Rates of survival and recurrence are presented here
at a follow-up of two years. A reanalysis as of June 1,
2001, produced essentially the same results for all
the major end points of the study.
Events
As of February 2001, 365 (20 percent) of the
1805 eligible patients had died. Of the 365 deaths,
61 occurred postoperatively, 231 were related to rec-
tal cancer  (growth of the primary tumor [in cases of
macroscopically incomplete resection] or recurrence),
and 70 were not related to rectal cancer. In three pa-
tients, the cause of death was unknown.
Local recurrence occurred in 87 patients. Of these
87 patients, 45 (52 percent) had local recurrence
alone, 28 (32 percent) had both local and distant re-
currences, and 14 (16 percent) had local recurrence
after distant metastasis was found at surgery (in 9 pa-
tients) or during follow-up (in 5). A total of 227 pa-
tients were found to have only distant recurrence.
Overall Survival
The rate of overall survival at two years was 82.0
percent in the group assigned to radiotherapy before
surgery and 81.8 percent in the group assigned to
surgery alone (P=0.84) (Fig. 1). The hazard ratio
for death in the group assigned to surgery alone as
compared with the group assigned to preoperative
radiotherapy was 1.02 (95 percent confidence inter-
val, 0.83 to 1.25).
Local Recurrence
The rate of local recurrence at two years was 5.3
percent in the population of 1748 patients who un-
derwent a macroscopically complete local resection.
The rates of local recurrence at two years were 2.4
percent in the group assigned to radiotherapy before
surgery and 8.2 percent in the group assigned to sur-
gery alone (P<0.001) (Fig. 2). According to a univari-
ate analysis, the hazard ratio for local recurrence in the
group assigned to surgery alone as compared with the
group assigned to preoperative radiotherapy plus sur-
gery was 3.42 (95 percent confidence interval, 2.05
to 5.71).
In the univariate analyses, treatment-group assign-
ment (P<0.001), the location of the tumor (distance
of the tumor from the anal verge) (P=0.003), and
the tumor–node–metastasis (TNM) stage (P<0.001)
Figure 1. Rates of Overall Survival in the Population of 1805 Eligible Patients, According to Treatment
Group.
At two years, the rate of overall survival was 82.0 percent in the group assigned to radiotherapy and
surgery and 81.8 percent in the group assigned to surgery alone (P=0.84).
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were significant predictors of the risk of local recur-
rence. In the multivariate Cox regression analysis (Ta-
ble 3), the treatment-group assignment (P<0.001),
the tumor location (P=0.03), and the TNM stage
(P<0.001) were independent predictors of the risk
of local recurrence, whereas the type of resection
(P=0.90) had no independent prognostic value with
respect to this end point.
Univariate subgroup analyses showed that preop-
erative radiotherapy reduced the risk of local recur-
rence significantly in patients who had tumors with
an inferior margin less than or equal to 5 cm (P=
0.05) or 5.1 to 10 cm (P<0.001) from the anal verge
(Table 4). Radiotherapy had no significant effect on
tumors located 10.1 to 15 cm from the anal verge
(P=0.17). For TNM stage II and III tumors, pre-
operative radiotherapy had a significant beneficial ef-
fect (P=0.01 and P<0.001, respectively), which was
not observed for TNM stage I and IV tumors (P=
0.15 and P=0.25, respectively). However, tests for
interaction among the tumor location, TNM stage,
and treatment-group assignment in a multivariate
analysis showed no significant interaction between
tumor location and treatment-group assignment (P=
0.08) or between the TNM stage and treatment-
group assignment (P=0.61), suggesting that the treat-
Figure 2. Rates of Local Recurrence in the Population of 1748 Eligible Patients Who Underwent Mac-
roscopically Complete Local Resection, According to Treatment Group.
At two years, the rate of local recurrence was 2.4 percent in the group assigned to radiotherapy and
surgery and 8.2 percent in the group assigned to surgery alone (P<0.001).
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*A variable was included in the multivariate analysis if its P value in the
univariate analysis was less than 0.10. Patients with missing data were ex-
cluded from the analysis of local recurrence. Twenty-eight patients without
a tumor (TNM stage 0) were excluded from the multivariate analysis be-
cause they were not at risk for local recurrence. CI denotes confidence in-
terval and TNM tumor–node–metastasis.
†A Hartmann resection is a low anterior resection without the construc-
tion of an anastomosis.
TABLE 3. RESULTS OF MULTIVARIATE COX REGRESSION ANALYSIS 
OF LOCAL RECURRENCE AMONG THE 1748 ELIGIBLE PATIENTS 
WITH A MACROSCOPICALLY COMPLETE LOCAL RESECTION.*
VARIABLE HAZARD RATIO (95% CI) P VALUE
Treatment group
Radiotherapy and surgery
Surgery alone
1.00
3.41 (2.05–5.70)
<0.001
Distance of tumor from anal verge
10.1–15 cm
5.1–10 cm
«5 cm
1.00 
2.13 (1.13–4.01)
2.78 (1.22–6.31)
0.03
0.02
0.02
Type of resection
Low anterior
Abdominoperineal
Hartmann†
1.00
1.15 (0.59–2.24)
1.16 (0.42–3.25)
0.90
0.68
0.78
TNM stage
I
II
III
IV (distant metastases but complete
local resection)
1.00
3.44 (1.26–9.39)
9.69 (3.89–24.2)
16.2 (5.40–48.6)
<0.001
0.02
<0.001
<0.001
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ment effect did not differ among the subgroups an-
alyzed (data not shown).
Distant Recurrence
The rate of distant recurrence at two years was
14.8 percent in the group assigned to radiotherapy
and surgery and 16.8 percent in the group assigned
to surgery alone (P=0.87). The hazard ratio for dis-
tant recurrence in the surgery-only group as com-
pared with the radiotherapy-plus-surgery group was
1.02 (95 percent confidence interval, 0.80 to 1.30).
Overall Recurrence
The overall rate of recurrence (the rate of local re-
currence and distant recurrence) at two years was
16.1 percent in the group assigned to radiotherapy
and surgery and 20.9 percent in the group assigned
to surgery alone (P=0.09). The hazard ratio for any
recurrence in the surgery-only group as compared
with the radiotherapy-plus-surgery group was 1.21
(95 percent confidence interval, 0.97 to 1.52).
DISCUSSION
In this trial, we evaluated the efficacy of short-term
preoperative radiotherapy combined with standard-
ized total mesorectal excision in patients with resec-
table rectal cancer. We found that radiotherapy before
total mesorectal excision can improve local control
of disease.
Reported rates of local control after surgery for
rectal cancer vary widely. In studies of conventional,
nonstandardized surgery, usually with a minimal fol-
low-up of five years, rates of local recurrence have
been 15 to 45 percent.3-5 By contrast, surgeons who
specialize in total mesorectal excision report local-
recurrence rates of 7 percent or less.9-11 The low rate
of local recurrence in the group assigned to total
mesorectal excision only in our study (8.2 percent at
two years) demonstrates that similar excellent results
can be achieved by other surgeons at multiple cen-
ters after they are trained in the procedure.
We found that preoperative radiotherapy further
reduced the two-year rate of local recurrence from
*Patients with missing data were excluded from the analysis of local recurrence. Twenty-eight pa-
tients without a tumor (TNM stage 0) were excluded from the multivariate analysis because they
were not at risk for local recurrence. In a Cox proportional-hazards analysis of age (as a continuous
variable), the hazard ratio for local recurrence at two years was 0.99 (95 percent confidence interval,
0.95 to 1.04; P=0.77) in the group of 873 patients assigned to radiotherapy and surgery and 1.01
(95 percent confidence interval, 0.99 to 1.04; P=0.21) in the group of 875 patients assigned to sur-
gery alone. TNM denotes tumor–node–metastasis.
†A Hartmann resection is a low anterior resection without the construction of an anastomosis.
TABLE 4. RESULTS OF UNIVARIATE LOG-RANK ANALYSES OF TWO-YEAR RATES 
OF LOCAL RECURRENCE AMONG THE 1748 ELIGIBLE PATIENTS 
WITH A MACROSCOPICALLY COMPLETE LOCAL RESECTION, 
ACCORDING TO SELECTED PROGNOSTIC VARIABLES.*
VARIABLE RADIOTHERAPY PLUS SURGERY SURGERY ALONE P VALUE
NO. OF
PATIENTS
AT RISK
LOCAL
RECURRENCE
AT 2 YR
NO. OF
PATIENTS
AT RISK
LOCAL
RECURRENCE
AT 2 YR
% %
Overall 873 2.4 875 8.2 <0.001
Sex
Male
Female
555
318
2.5
2.2
557
318
7.2
9.8
<0.001
<0.001
Distance of tumor from anal verge
10.1–15 cm
5.1–10 cm
«5 cm
262
372
237
1.3
1.0
5.8
271
350
253
3.8
10.1
10.0
0.17
<0.001
0.05
Type of resection
Low anterior
Abdominoperineal
Hartmann†
577
248
47
1.2
4.9
3.2
603
232
39
7.3
10.1
10.7
<0.001
0.02
0.18
TNM stage
I
II
III
IV (distant metastases but
complete local resection)
265
251
298
47
0.5
1.0
4.3
10.1
244
241
324
48
0.7
5.7
15.0
23.8
0.15
0.01
<0.001
0.25
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8.2 percent to 2.4 percent, an indication of the value
of preoperative radiotherapy when used in conjunc-
tion with standardized surgery. In the Swedish Rectal
Cancer Trial, the reduction in the rate of local recur-
rence at five years from 27 percent in the surgery-
only group to 11 percent in the radiotherapy-plus-
surgery group improved the rate of overall survival
at this time point from 48 percent in the surgery-
only group to 58 percent in the combined-treatment
group.7 An effect of preoperative radiotherapy on
overall survival has not yet been detected in our trial,
probably because of the small number of local recur-
rences and the short follow-up. However, we believe
that a median follow-up time of 24.9 months is suf-
ficient to detect the effect of preoperative radiother-
apy on local recurrences, 55 to 80 percent of which
occur during the first 2 years after surgery, with the
peak rate at 6 to 12 months.4,21,22
The beneficial effect of preoperative radiotherapy
in our trial was observed for all tumor locations 15 cm
or less from the anal verge and for all TNM stages.
However, in a univariate subgroup analysis, the effect
was not significant in patients who had tumors with
an inferior margin more than 10 cm from the anal
verge and in patients who had TNM stage I or IV
tumors. Nevertheless, multivariate tests indicated that
the treatment effect probably did not differ among
subgroups defined according to tumor location, TNM
stage, and treatment assignment. Therefore, consider-
ing the difficulties involved in predicting the location
of tumors high above the anal verge and in determin-
ing the TNM stage preoperatively, the decision not to
irradiate before surgery should be carefully considered.
Preoperative radiotherapy does not result in “down-
staging”23 and is therefore not suitable for locally ad-
vanced tumors. To avoid short-term irradiation of such
tumors, we advocate accurate preoperative imaging
(for example, computed tomography or magnetic res-
onance imaging). This lack of down-staging explains
why short-term preoperative radiotherapy has no ef-
fect on sphincter preservation, which is often an end
point in conventional trials of long-term radiotherapy.
Concern has been expressed about the side effects
of hypofractionated radiation.24 In the Stockholm I tri-
al25 and Imperial Cancer Research Fund trial,26 post-
operative mortality was higher among patients who
received radiotherapy than among those who did not.
In both trials, a suboptimal irradiation technique in-
creased the treated volume considerably. In the Swed-
ish Rectal Cancer Trial, postoperative mortality did
not increase with radiation, provided that radiothera-
py was optimal.27 In our trial, there was no difference
in in-hospital mortality between the two groups. In
the Swedish Rectal Cancer Trial, however, there was
more incontinence among patients who underwent
preoperative irradiation and subsequently underwent
a sphincter-preserving surgery.28
In conclusion, total mesorectal excision can signif-
icantly decrease the risk of local recurrence of resecta-
ble rectal cancer. This result was achieved in a large,
multicenter trial that included extensive instruction
and quality control of the surgical technique. In this
large group of patients who underwent standardized
surgery, short-term preoperative radiotherapy further
reduced the risk of local recurrence.
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